World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
69448
World Ranking
10640
National Ranking
5471

Thomas J. Lynch publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Thomas J. Lynch sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 363 publications — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Thomas J. Lynch D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Thomas J. Lynch sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Thomas J. Lynch is affiliated with Johns Hopkins University in the United States. Their research primarily spans the fields of Medicine and Psychology, with a focus on Clinical Psychology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Social Psychology, and Pediatrics, Perinatology and Child Health.

Their work covers a range of topics including Breast Cancer Treatment Studies, Suicide and Self-Harm Studies, Mental Health Treatment and Access, Counseling Practices and Supervision, Personality Disorders and Psychopathology, Psychotherapy Techniques and Applications, and Psychological Testing and Assessment.

Thomas J. Lynch has contributed to several publication venues, including UNC Libraries, Pathology, Archives of Suicide Research, Canadian Journal of Emergency Medicine, and Case Reports in Gastroenterology.

Notable recent papers include:

  • The Content of Patient-Identified Suicidal Drivers within CAMS Treatment Planning (2022, Archives of Suicide Research)
  • LO48: Pediatric cannabinoid hyperemesis syndrome in the emergency department: a 5-year retrospective review (2020, Canadian Journal of Emergency Medicine)
  • The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS) (2022, UNC Libraries)
  • Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 (2020, UNC Libraries)
  • Breast implant-associated ALCL (BIA-ALCL). Experience at Douglass Hanly Moir Pathology (2023, Pathology)

Frequent co-authors include Rhonda M. Merwin, Prudence F. Cuper, Kibby McMahon, Leonard Hsu, and Kwan Yee Tsu.

Best Publications

  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

    Thomas J Lynch;Daphne W Bell;Raffaella Sordella;Sarada Gurubhagavatula

  • Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

    Jennifer S. Temel;Joseph A. Greer;Alona Muzikansky;Emily R. Gallagher

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch

  • Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

    Alice T. Shaw;Beow Y. Yeap;Mari Mino-Kenudson;Subba R. Digumarthy

  • Detection of Mutations in EGFR in Circulating Lung-Cancer Cells

    Shyamala Maheswaran;Lecia V. Sequist;Sunitha Nagrath;Lindsey Ulkus

  • Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

    Thomas J. Lynch;Igor Bondarenko;Alexander Luft;Piotr Serwatowski

  • Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

    Eunice L. Kwak;Raffaella Sordella;Daphne W. Bell;Nadia Godin-Heymann

  • First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

    Lecia V. Sequist;Renato G. Martins;David Spigel;Steven M. Grunberg

  • Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer

    Lecia V. Sequist;Daphne W. Bell;Thomas J. Lynch;Daniel A. Haber

  • Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

    Daphne W. Bell;Thomas J. Lynch;Sara M. Haserlat;Patricia L. Harris

  • Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.

    Scott J. Rodig;Mari Mino-Kenudson;Sanja Dacic;Beow Y. Yeap

  • Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non–Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care

    Jennifer S. Temel;Joseph A. Greer;Joseph A. Greer;Joseph A. Greer;Sonal Admane;Sonal Admane;Sonal Admane;Emily R. Gallagher;Emily R. Gallagher;Emily R. Gallagher

  • Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

    David M. Jackman;Beow Y. Yeap;Lecia V. Sequist;Neal Lindeman

  • Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

    Thomas J. Lynch;Taral Patel;Luke Dreisbach;Michael McCleod

  • Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor:Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer

    Lecia V. Sequist;Benjamin Besse;Thomas J. Lynch;Vincent A. Miller

  • Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management

    Thomas J. Lynch;Ed S. Kim;Beth Eaby;Jody Garey

  • Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

    Dora Dias‐Santagata;Sara Akhavanfard;Serena S. David;Kathy Vernovsky

  • XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy

    Sarada Gurubhagavatula;Geoffrey Liu;Sohee Park;Wei Zhou

Frequent Co-Authors

John C. Wain
John C. Wain Harvard University
David C. Christiani
David C. Christiani Harvard University
Geoffrey Liu
Geoffrey Liu Princess Margaret Cancer Centre
Bruce A. Chabner
Bruce A. Chabner Harvard University
Lecia V. Sequist
Lecia V. Sequist Harvard University
Bruce E. Johnson
Bruce E. Johnson Harvard University
Daniel A. Haber
Daniel A. Haber Harvard University
Pasi A. Jänne
Pasi A. Jänne Harvard University
Jennifer S. Temel
Jennifer S. Temel Harvard University
Donna Neuberg
Donna Neuberg Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to several related online degrees and alternative career paths in healthcare. Many students interested in patient care consider direct entry online msn programs for those without a nursing background. These programs offer a pathway into advanced practice nursing roles efficiently, even for non-nurses.

For applicants prioritizing accessibility, there are also nursing schools with high acceptance rates, making entry into the nursing field more achievable. In addition, some institutions offer opportunities for aspiring nurses by providing nursing schools that don't require teas test as part of their admissions process, reducing obstacles for prospective students.

If you are interested in the administrative side of healthcare, consider accredited medical billing and coding programs. There are numerous accredited medical billing and coding schools online with financial aid options available, making this career path more accessible and affordable.

Best Scientists Citing Thomas J. Lynch

Trending Scientists